Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis
Open accessThe DOI matches its Crossref record.
Abstract
Aims Experimental studies have suggested that constant intravenous infusion would be preferable to conventional intermittent bolus administration of beta‐lactam antibiotics for serious Gram‐negative infections. Severe melioidosis (Burkholderia pseudomallei infection) carries a mortality over 40% despite treatment with high dose ceftazidime. The aim of this study was to measure the pharmacokinetic and pharmacodynamic effects of continuous infusion of ceftazidime vs intermittent bolus dosing in septicaemic melioidosis. Methods Patients with suspected septicaemic melioidosis were randomised to receive ceftazidime 40 mg kg−1 8 hourly by bolus injection or 4 mg kg−1 h−1 by constant infusion following a 12 mg kg−1 priming dose and pharmacokinetic and pharmacodynamic parameters were compared. Results Of the 34 patients studied 16 (59%) died. Twenty patients had cultures positive for B. pseudomallei of whom 12 (60%) died. The median MIC 90 of B. pseudomallei was 2 mg l−1, giving a minimum target concentration (4*MIC) of 8 mg l−1. The median (range) estimated total apparent volume of distribution, systemic clearance and terminal elimination half‐lives of ceftazidime were 0.468 (0.241–0.573) l kg−1, 0.058 (0.005–0.159) l kg−1 h−1 and 7.74 (1.95–44.71) h, respectively. Clearance of ceftazidime and creatinine clearance were correlated closely (r = 0.71; P < 0.001) and there was no evidence of significant nonrenal clearance. Conclusions Simulations based on these data and the ceftazidime sensitivity of the B. pseudomallei isolates indicated that administration by constant infusion would allow significant dose reduction and cost saving. With conventional 8 h intermittent dosing to patients with normal renal function, plasma ceftazidime concentrations could fall below the target concentration but this would be unlikely with a constant infusion. Correction for renal failure, which is common in patients with meliodosis is Clearance =k* creatinine clearance where k = 0.72. Calculation of a loading dose gives median (range) values of loading dose, DL of 18.7 mg kg−1 (9.5–23) and infusion rate I = 3.5 mg kg−1 h−1 (0.4–13) (which equals 84 mg kg−1 day−1). A nomogram for adjustment in renal failure is given.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 43
- 10.1093/jac/24.3.281 · doi:10.1093/jac/24.3.281
- 10.1128/AAC.35.3.399 · DOI · Paper page
- 10.1093/infdis/158.4.831 · DOI · Paper page
- 10.1128/AAC.32.3.289 · DOI · Paper page
- 10.1159/000138851 · doi:10.1159/000138851
- 10.1128/AAC.38.5.931 · DOI · Paper page
- 10.1093/jac/43.2.309 · DOI
- 10.1086/514622 · DOI · Paper page
- 10.1177/106002809502900413 · doi:10.1177/106002809502900413
- 10.1093/infdis/159.5.890 · DOI · Paper page
- 10.1016/S0140-6736(89)90768-X · DOI
- 10.1093/clinids/19.5.846 · doi:10.1093/clinids/19.5.846
- 10.1093/jac/24.3.295 · DOI
- 10.1093/jac/33.1.145 · doi:10.1093/jac/33.1.145
- 10.1093/clinids/21.6.1498 · DOI
- 10.1099/00222615-33-2-121 · doi:10.1099/00222615-33-2-121
- 10.1136/jcp.42.6.645 · doi:10.1136/jcp.42.6.645
- 10.1016/0035-9203(95)90104-3 · doi:10.1016/0035-9203(95)90104-3
- 10.1007/BF00542421 · doi:10.1007/bf00542421
- 10.1128/AAC.24.3.343 · doi:10.1128/aac.24.3.343
- 10.1159/000180580 · DOI · Paper page
- 10.1111/j.1365-2125.1989.tb05427.x · doi:10.1111/j.1365-2125.1989.tb05427.x
- 10.1093/ije/23.5.1082 · DOI · Paper page
- 10.2165/00003495-198529020-00002 · doi:10.2165/00003495-198529020-00002
- 10.1128/AAC.23.6.892 · doi:10.1128/aac.23.6.892
- 10.3109/00365548909035704 · doi:10.3109/00365548909035704
- 10.1128/AAC.25.5.638 · doi:10.1128/aac.25.5.638
- 10.1002/j.1552-4604.1989.tb03337.x · doi:10.1002/j.1552-4604.1989.tb03337.x
- 10.1093/jac/40.1.125 · DOI
- Ganzinger U, 1987, Pharmacokinetics of ceftazidime and netilimicin in patients with sepsis, Int J Pharmacol Ther Toxicol, 25, 354
- Rondanelli R, 1986, Ceftazidime in the treatment of Pseudomonas infections in intensive‐care patients, Int J Clin Pharmacol Ther Toxicol, 24, 457
- 10.1007/BF01709707 · doi:10.1007/bf01709707
- 10.1128/AAC.37.3.464 · doi:10.1128/aac.37.3.464
- 10.1016/S0140-6736(86)92106-9 · doi:10.1016/s0140-6736(86)92106-9
- 10.1093/jac/28.1.95 · doi:10.1093/jac/28.1.95
- 10.1093/jac/15.3.365 · doi:10.1093/jac/15.3.365
- 10.1016/0195-6701(90)90076-Z · doi:10.1016/0195-6701(90)90076-z
- 10.1128/AAC.32.3.298 · DOI
- 10.1093/jac/40.2.269 · DOI
- Benko AS, 1996, Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram‐negative infections, Antimicrob Agents Chemother, 40, 691, 10.1128/AAC.40.3.691 · DOI · Paper page
- 10.1128/AAC.41.9.2053 · DOI
- 10.1002/j.1875-9114.1985.tb03424.x · DOI
- Couldry R, 1998, Continuous infusion of ceftazidime with an elastomeric infusion device, Am J Health Syst Pharm, 55, 145, 10.1093/ajhp/55.2.145 · doi:10.1093/ajhp/55.2.145
Cited by
Melioidosis: Epidemiology, Pathophysiology, and Management
Cheng, A. C., & Currie, B. J. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.383-416.2005 · Cited by 1,464
Pharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862
White, N. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13374-0 · Cited by 760
Self-citationSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414
Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408
Metadata
- Authors
- Angus, B. J., Smith, M. D., Suputtamongkol, Y., Mattie, H., Walsh, A. L., Wuthiekanun, V., Chaowagul, W., & White, N. J.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2000-08
- Volume
- 50
- Issue
- 2
- Pages
- 184-191
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2057650704
- Cited by
- 114
- References
- 0
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. https://app.cochat.ai/papers/10.1111/j.1365-2125.2000.00179.x
- The paper
- Angus, B. J., Smith, M. D., Suputtamongkol, Y., Mattie, H., Walsh, A. L., Wuthiekanun, V., Chaowagul, W., & White, N. J. (2000). Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2000.00179.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.